Goldberg Marc E. 4
4 · ENANTA PHARMACEUTICALS INC · Filed Mar 28, 2013
Insider Transaction Report
Form 4
Goldberg Marc E.
Director
Transactions
- Conversion
Common Stock
2013-03-26+132,494→ 604,467 total(indirect: By Partnership) - Conversion
Series G-2 Convertible Preferred Stock
2013-03-26−571,053→ 0 total(indirect: By Partnership)→ Common Stock (132,494 underlying) - Conversion
Common Stock
2013-03-26+471,973→ 471,973 total(indirect: By Partnership) - Conversion
Series E Convertible Preferred Stock
2013-03-26−1,545,997→ 0 total(indirect: By Partnership)→ Common Stock (471,973 underlying)
Footnotes (3)
- [F1]The Series E Convertible Preferred Stock has no expiration date, and each share of Series E Convertible Preferred Stock converted automatically into approximately 0.30529 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
- [F2]These shares are held by BioVentures Investors Limited Partnership II, and are shares for which Mr. Goldberg may be deemed to share voting and investment control. Mr. Goldberg disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.
- [F3]The Series G-2 Convertible Preferred Stock has no expiration date, and each share of Series G-2 Convertible Preferred Stock converted automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.